Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 154

1.

Complexity of PEComas : Diagnostic approach, molecular background, clinical management.

Utpatel K, Calvisi DF, Köhler G, Kühnel T, Niesel A, Verloh N, Vogelhuber M, Neu R, Hosten N, Schildhaus HU, Dietmaier W, Evert M.

Pathologe. 2019 Jul 15. doi: 10.1007/s00292-019-0612-5. [Epub ahead of print] Review.

PMID:
31309284
2.

Combined Treatment with MEK and mTOR Inhibitors is Effective in In Vitro and In Vivo Models of Hepatocellular Carcinoma.

Liu X, Hu J, Song X, Utpatel K, Zhang Y, Wang P, Lu X, Zhang J, Xu M, Su T, Che L, Wang J, Evert M, Calvisi DF, Chen X.

Cancers (Basel). 2019 Jul 3;11(7). pii: E930. doi: 10.3390/cancers11070930.

3.

[Erratum to: Complexity of PEComas : Diagnostic approach, molecular background, clinical management].

Utpatel K, Calvisi DF, Köhler G, Kühnel T, Niesel A, Verloh N, Vogelhuber M, Neu R, Hosten N, Schildhaus HU, Dietmaier W, Evert M.

Pathologe. 2019 Jul;40(4):454. doi: 10.1007/s00292-019-0636-x. German. No abstract available.

PMID:
31263908
4.

Loss of Fbxw7 synergizes with activated AKT signaling to promote c-Myc dependent cholangiocarcinogenesis.

Wang J, Wang H, Peters M, Ding N, Ribback S, Utpatel K, Cigliano A, Dombrowski F, Xu M, Chen X, Song X, Che L, Evert M, Cossu A, Gordan J, Zeng Y, Chen X, Calvisi DF.

J Hepatol. 2019 Jun 10. pii: S0168-8278(19)30342-3. doi: 10.1016/j.jhep.2019.05.027. [Epub ahead of print]

PMID:
31195063
5.

[Complexity of PEComas : Diagnostic approach, molecular background, clinical management (German version)].

Utpatel K, Calvisi DF, Köhler G, Kühnel T, Niesel A, Verloh N, Vogelhuber M, Neu R, Hosten N, Schildhaus HU, Dietmaier W, Evert M.

Pathologe. 2019 Jul;40(4):443-453. doi: 10.1007/s00292-019-0614-3. Review. German. Erratum in: Pathologe. 2019 Jul 1;:.

PMID:
31165234
6.

Cholangiocarcinoma: State-of-the-art knowledge and challenges.

Banales JM, Cardinale V, Macias RIR, Andersen JB, Braconi C, Carpino G, Alvaro D, Calvisi DF.

Liver Int. 2019 May;39 Suppl 1:5-6. doi: 10.1111/liv.14101. No abstract available.

PMID:
31111668
7.

MicroRNA-203 impacts on the growth, aggressiveness and prognosis of hepatocellular carcinoma by targeting MAT2A and MAT2B genes.

Simile MM, Peitta G, Tomasi ML, Brozzetti S, Feo CF, Porcu A, Cigliano A, Calvisi DF, Feo F, Pascale RM.

Oncotarget. 2019 Apr 19;10(29):2835-2854. doi: 10.18632/oncotarget.26838. eCollection 2019 Apr 19.

8.

The mTORC2-Akt1 Cascade Is Crucial for c-Myc to Promote Hepatocarcinogenesis in Mice and Humans.

Xu Z, Xu M, Liu P, Zhang S, Shang R, Qiao Y, Che L, Ribback S, Cigliano A, Evert K, Pascale RM, Dombrowski F, Evert M, Chen X, Calvisi DF, Chen X.

Hepatology. 2019 May 7. doi: 10.1002/hep.30697. [Epub ahead of print]

PMID:
31062368
9.

Functional role of SGK3 in PI3K/Pten driven liver tumor development.

Cao H, Xu Z, Wang J, Cigliano A, Pilo MG, Ribback S, Zhang S, Qiao Y, Che L, Pascale RM, Calvisi DF, Chen X.

BMC Cancer. 2019 Apr 11;19(1):343. doi: 10.1186/s12885-019-5551-2.

10.

Reply (to LTE HEP-19-0392).

Chen X, Monga SP, Calvisi DF.

Hepatology. 2019 Apr 8. doi: 10.1002/hep.30644. [Epub ahead of print]

PMID:
30958900
11.

Cholesterol biosynthesis supports the growth of hepatocarcinoma lesions depleted of fatty acid synthase in mice and humans.

Che L, Chi W, Qiao Y, Zhang J, Song X, Liu Y, Li L, Jia J, Pilo MG, Wang J, Cigliano A, Ma Z, Kuang W, Tang Z, Zhang Z, Shui G, Ribback S, Dombrowski F, Evert M, Pascale RM, Cossu C, Pes GM, Osborne TF, Calvisi DF, Chen X, Chen L.

Gut. 2019 Apr 6. pii: gutjnl-2018-317581. doi: 10.1136/gutjnl-2018-317581. [Epub ahead of print]

12.

Experimental models to unravel the molecular pathogenesis, cell of origin and stem cell properties of cholangiocarcinoma.

Vicent S, Lieshout R, Saborowski A, Verstegen MMA, Raggi C, Recalcati S, Invernizzi P, van der Laan LJW, Alvaro D, Calvisi DF, Cardinale V.

Liver Int. 2019 May;39 Suppl 1:79-97. doi: 10.1111/liv.14094. Review.

PMID:
30851232
13.

TEA Domain Transcription Factor 4 Is the Major Mediator of Yes-Associated Protein Oncogenic Activity in Mouse and Human Hepatoblastoma.

Zhang J, Liu P, Tao J, Wang P, Zhang Y, Song X, Che L, Sumazin P, Ribback S, Kiss A, Schaff Z, Cigliano A, Dombrowski F, Cossu C, Pascale RM, Calvisi DF, Monga SP, Chen X.

Am J Pathol. 2019 May;189(5):1077-1090. doi: 10.1016/j.ajpath.2019.01.016. Epub 2019 Feb 19.

PMID:
30794805
14.

MEK inhibition suppresses K-Ras wild-type cholangiocarcinoma in vitro and in vivo via inhibiting cell proliferation and modulating tumor microenvironment.

Wang P, Song X, Utpatel K, Shang R, Yang YM, Xu M, Zhang J, Che L, Gordan J, Cigliano A, Seki E, Evert M, Calvisi DF, Hu X, Chen X.

Cell Death Dis. 2019 Feb 11;10(2):120. doi: 10.1038/s41419-019-1389-4.

15.

Axis inhibition protein 1 (Axin1) Deletion-Induced Hepatocarcinogenesis Requires Intact β-Catenin but Not Notch Cascade in Mice.

Qiao Y, Wang J, Karagoz E, Liang B, Song X, Shang R, Evert K, Xu M, Che L, Evert M, Calvisi DF, Tao J, Wang B, Monga SP, Chen X.

Hepatology. 2019 Feb 8. doi: 10.1002/hep.30556. [Epub ahead of print]

PMID:
30737831
16.

Oncogenic potential of N-terminal deletion and S45Y mutant β-catenin in promoting hepatocellular carcinoma development in mice.

Qiao Y, Xu M, Tao J, Che L, Cigliano A, Monga SP, Calvisi DF, Chen X.

BMC Cancer. 2018 Nov 12;18(1):1093. doi: 10.1186/s12885-018-4870-z.

17.

Focal adhesion kinase activation limits efficacy of Dasatinib in c-Myc driven hepatocellular carcinoma.

Liu X, Song X, Zhang J, Xu Z, Che L, Qiao Y, Ortiz Pedraza Y, Cigliano A, Pascale RM, Calvisi DF, Liu Y, Chen X.

Cancer Med. 2018 Dec;7(12):6170-6181. doi: 10.1002/cam4.1777. Epub 2018 Oct 28.

18.

Alterations of methionine metabolism in hepatocarcinogenesis: the emergent role of glycine N-methyltransferase in liver injury.

Simile MM, Latte G, Feo CF, Feo F, Calvisi DF, Pascale RM.

Ann Gastroenterol. 2018 Sep-Oct;31(5):552-560. doi: 10.20524/aog.2018.0288. Epub 2018 Jul 12. Review.

19.

The complex role of bone morphogenetic protein 9 in liver damage and regeneration: New evidence from in vivo and in vitro studies.

Pascale RM, Feo F, Calvisi DF.

Liver Int. 2018 Sep;38(9):1547-1549. doi: 10.1111/liv.13925. No abstract available.

PMID:
30145848
20.

Combined CDK4/6 and Pan-mTOR Inhibition Is Synergistic Against Intrahepatic Cholangiocarcinoma.

Song X, Liu X, Wang H, Wang J, Qiao Y, Cigliano A, Utpatel K, Ribback S, Pilo MG, Serra M, Gordan JD, Che L, Zhang S, Cossu A, Porcu A, Pascale RM, Dombrowski F, Hu H, Calvisi DF, Evert M, Chen X.

Clin Cancer Res. 2019 Jan 1;25(1):403-413. doi: 10.1158/1078-0432.CCR-18-0284. Epub 2018 Jul 3.

PMID:
30084835
21.

Deregulation of methionine metabolism as determinant of progression and prognosis of hepatocellular carcinoma.

Pascale RM, Feo CF, Calvisi DF, Feo F.

Transl Gastroenterol Hepatol. 2018 Jun 29;3:36. doi: 10.21037/tgh.2018.06.04. eCollection 2018. Review.

22.

Oncogene-dependent addiction to carbohydrate-responsive element binding protein in hepatocellular carcinoma.

Ribback S, Che L, Pilo MG, Cigliano A, Latte G, Pes GM, Porcu A, Pascale RM, Li L, Qiao Y, Dombrowski F, Chen X, Calvisi DF.

Cell Cycle. 2018;17(12):1496-1512. doi: 10.1080/15384101.2018.1489182. Epub 2018 Jul 18.

23.

Notch2 controls hepatocyte-derived cholangiocarcinoma formation in mice.

Wang J, Dong M, Xu Z, Song X, Zhang S, Qiao Y, Che L, Gordan J, Hu K, Liu Y, Calvisi DF, Chen X.

Oncogene. 2018 Jun;37(24):3229-3242. doi: 10.1038/s41388-018-0188-1. Epub 2018 Mar 16.

24.

Hippo Cascade Controls Lineage Commitment of Liver Tumors in Mice and Humans.

Zhang S, Wang J, Wang H, Fan L, Fan B, Zeng B, Tao J, Li X, Che L, Cigliano A, Ribback S, Dombrowski F, Chen B, Cong W, Wei L, Calvisi DF, Chen X.

Am J Pathol. 2018 Apr;188(4):995-1006. doi: 10.1016/j.ajpath.2017.12.017. Epub 2018 Jan 31.

25.

Efficacy of MEK inhibition in a K-Ras-driven cholangiocarcinoma preclinical model.

Dong M, Liu X, Evert K, Utpatel K, Peters M, Zhang S, Xu Z, Che L, Cigliano A, Ribback S, Dombrowski F, Cossu A, Gordan J, Calvisi DF, Evert M, Liu Y, Chen X.

Cell Death Dis. 2018 Jan 18;9(2):31. doi: 10.1038/s41419-017-0183-4.

26.

Loss of Pten synergizes with c-Met to promote hepatocellular carcinoma development via mTORC2 pathway.

Xu Z, Hu J, Cao H, Pilo MG, Cigliano A, Shao Z, Xu M, Ribback S, Dombrowski F, Calvisi DF, Chen X.

Exp Mol Med. 2018 Jan 5;50(1):e417. doi: 10.1038/emm.2017.158.

27.

Hepatocellular glycogenotic foci after combined intraportal pancreatic islet transplantation and knockout of the carbohydrate responsive element binding protein in diabetic mice.

Ribback S, Sonke J, Lohr A, Frohme J, Peters K, Holm J, Peters M, Cigliano A, Calvisi DF, Dombrowski F.

Oncotarget. 2017 Nov 1;8(61):104315-104329. doi: 10.18632/oncotarget.22234. eCollection 2017 Nov 28.

28.

Cholesterol overload in the liver aggravates oxidative stress-mediated DNA damage and accelerates hepatocarcinogenesis.

Enríquez-Cortina C, Bello-Monroy O, Rosales-Cruz P, Souza V, Miranda RU, Toledo-Pérez R, Luna-López A, Simoni-Nieves A, Hernández-Pando R, Gutiérrez-Ruiz MC, Calvisi DF, Marquardt JU, Bucio L, Gomez-Quiroz LE.

Oncotarget. 2017 Oct 24;8(61):104136-104148. doi: 10.18632/oncotarget.22024. eCollection 2017 Nov 28.

29.

Deregulated c-Myc requires a functional HSF1 for experimental and human hepatocarcinogenesis.

Cigliano A, Pilo MG, Li L, Latte G, Szydlowska M, Simile MM, Paliogiannis P, Che L, Pes GM, Palmieri G, Sini MC, Cossu A, Porcu A, Vidili G, Seddaiu MA, Pascale RM, Ribback S, Dombrowski F, Chen X, Calvisi DF.

Oncotarget. 2017 Oct 3;8(53):90638-90650. doi: 10.18632/oncotarget.21469. eCollection 2017 Oct 31.

30.

Perioperative, Spatiotemporally Coordinated Activation of T and NK Cells Prevents Recurrence of Pancreatic Cancer.

Brooks J, Fleischmann-Mundt B, Woller N, Niemann J, Ribback S, Peters K, Demir IE, Armbrecht N, Ceyhan GO, Manns MP, Wirth TC, Kubicka S, Bernhardt G, Smyth MJ, Calvisi DF, Gürlevik E, Kühnel F.

Cancer Res. 2018 Jan 15;78(2):475-488. doi: 10.1158/0008-5472.CAN-17-2415. Epub 2017 Nov 27.

31.

Central role of mTORC1 downstream of YAP/TAZ in hepatoblastoma development.

Liu P, Calvisi DF, Kiss A, Cigliano A, Schaff Z, Che L, Ribback S, Dombrowski F, Zhao D, Chen X.

Oncotarget. 2017 Sep 1;8(43):73433-73447. doi: 10.18632/oncotarget.20622. eCollection 2017 Sep 26.

32.

[Nuclear Her2 expression in hepatocytes in liver disease].

Döring P, Pilo GM, Calvisi DF, Dombrowski F.

Pathologe. 2017 Nov;38(Suppl 2):211-217. doi: 10.1007/s00292-017-0351-4. Review. German.

PMID:
29018945
33.

Non-functioning gastroenteropancreatic (GEP) tumors: a 111In-Pentetreotide SPECT/CT diagnostic study.

Spanu A, Schillaci O, Piras B, Calvisi DF, Falchi A, Danieli R, Nuvoli S, Dore F, Madeddu G.

Am J Nucl Med Mol Imaging. 2017 Sep 1;7(4):181-194. eCollection 2017.

34.

Inhibition of HSF1 suppresses the growth of hepatocarcinoma cell lines in vitro and AKT-driven hepatocarcinogenesis in mice.

Cigliano A, Wang C, Pilo MG, Szydlowska M, Brozzetti S, Latte G, Pes GM, Pascale RM, Seddaiu MA, Vidili G, Ribback S, Dombrowski F, Evert M, Chen X, Calvisi DF.

Oncotarget. 2017 Apr 7;8(33):54149-54159. doi: 10.18632/oncotarget.16927. eCollection 2017 Aug 15.

35.

Tankyrase inhibitors suppress hepatocellular carcinoma cell growth via modulating the Hippo cascade.

Jia J, Qiao Y, Pilo MG, Cigliano A, Liu X, Shao Z, Calvisi DF, Chen X.

PLoS One. 2017 Sep 6;12(9):e0184068. doi: 10.1371/journal.pone.0184068. eCollection 2017.

36.

Transforming Growth Factor-β Promotes Liver Tumorigenesis in Mice via Up-regulation of Snail.

Moon H, Ju HL, Chung SI, Cho KJ, Eun JW, Nam SW, Han KH, Calvisi DF, Ro SW.

Gastroenterology. 2017 Nov;153(5):1378-1391.e6. doi: 10.1053/j.gastro.2017.07.014. Epub 2017 Jul 20.

PMID:
28734833
37.

Pan-mTOR inhibitor MLN0128 is effective against intrahepatic cholangiocarcinoma in mice.

Zhang S, Song X, Cao D, Xu Z, Fan B, Che L, Hu J, Chen B, Dong M, Pilo MG, Cigliano A, Evert K, Ribback S, Dombrowski F, Pascale RM, Cossu A, Vidili G, Porcu A, Simile MM, Pes GM, Giannelli G, Gordan J, Wei L, Evert M, Cong W, Calvisi DF, Chen X.

J Hepatol. 2017 Dec;67(6):1194-1203. doi: 10.1016/j.jhep.2017.07.006. Epub 2017 Jul 19.

38.

Animal models of biliary injury and altered bile acid metabolism.

Mariotti V, Strazzabosco M, Fabris L, Calvisi DF.

Biochim Biophys Acta Mol Basis Dis. 2018 Apr;1864(4 Pt B):1254-1261. doi: 10.1016/j.bbadis.2017.06.027. Epub 2017 Jul 11. Review.

39.

Glucose Catabolism in Liver Tumors Induced by c-MYC Can Be Sustained by Various PKM1/PKM2 Ratios and Pyruvate Kinase Activities.

Méndez-Lucas A, Li X, Hu J, Che L, Song X, Jia J, Wang J, Xie C, Driscoll PC, Tschaharganeh DF, Calvisi DF, Yuneva M, Chen X.

Cancer Res. 2017 Aug 15;77(16):4355-4364. doi: 10.1158/0008-5472.CAN-17-0498. Epub 2017 Jun 19.

40.

The burden of HIV-associated neurocognitive disorder (HAND) in post-HAART era: a multidisciplinary review of the literature.

Caruana G, Vidili G, Serra PA, Bagella P, Spanu A, Fiore V, Calvisi DF, Manetti R, Rocchitta G, Nuvoli S, Babudieri S, Simile MM, Madeddu G.

Eur Rev Med Pharmacol Sci. 2017 May;21(9):2290-2301. Review.

41.

A functional mammalian target of rapamycin complex 1 signaling is indispensable for c-Myc-driven hepatocarcinogenesis.

Liu P, Ge M, Hu J, Li X, Che L, Sun K, Cheng L, Huang Y, Pilo MG, Cigliano A, Pes GM, Pascale RM, Brozzetti S, Vidili G, Porcu A, Cossu A, Palmieri G, Sini MC, Ribback S, Dombrowski F, Tao J, Calvisi DF, Chen L, Chen X.

Hepatology. 2017 Jul;66(1):167-181. doi: 10.1002/hep.29183. Epub 2017 May 22.

42.

Role of the Notch signaling in cholangiocarcinoma.

Cigliano A, Wang J, Chen X, Calvisi DF.

Expert Opin Ther Targets. 2017 May;21(5):471-483. doi: 10.1080/14728222.2017.1310842. Epub 2017 Mar 30. Review.

PMID:
28326864
43.

Molecular profiling of intrahepatic cholangiocarcinoma: the search for new therapeutic targets.

Oliveira DV, Zhang S, Chen X, Calvisi DF, Andersen JB.

Expert Rev Gastroenterol Hepatol. 2017 Apr;11(4):349-356. doi: 10.1080/17474124.2017.1292127. Epub 2017 Feb 13.

PMID:
28162004
44.

Sulfatase 1: a new Jekyll and Hyde in hepatocellular carcinoma?

Pascale RM, Calvisi DF, Feo F.

Transl Gastroenterol Hepatol. 2016 May 18;1:43. doi: 10.21037/tgh.2016.05.04. eCollection 2016. No abstract available.

45.

Oncogene dependent requirement of fatty acid synthase in hepatocellular carcinoma.

Che L, Pilo MG, Cigliano A, Latte G, Simile MM, Ribback S, Dombrowski F, Evert M, Chen X, Calvisi DF.

Cell Cycle. 2017 Mar 19;16(6):499-507. doi: 10.1080/15384101.2017.1282586. Epub 2017 Jan 24.

46.

Nonstructural protein 5B promotes degradation of the NORE1A tumor suppressor to facilitate hepatitis C virus replication.

Arora P, Basu A, Schmidt ML, Clark GJ, Donninger H, Nichols DB, Calvisi DF, Kaushik-Basu N.

Hepatology. 2017 May;65(5):1462-1477. doi: 10.1002/hep.29049. Epub 2017 Mar 30.

47.

Jagged 1 is a major Notch ligand along cholangiocarcinoma development in mice and humans.

Che L, Fan B, Pilo MG, Xu Z, Liu Y, Cigliano A, Cossu A, Palmieri G, Pascale RM, Porcu A, Vidili G, Serra M, Dombrowski F, Ribback S, Calvisi DF, Chen X.

Oncogenesis. 2016 Dec 5;5(12):e274. doi: 10.1038/oncsis.2016.73.

48.

DNA-PKcs: A promising therapeutic target in human hepatocellular carcinoma?

Pascale RM, Joseph C, Latte G, Evert M, Feo F, Calvisi DF.

DNA Repair (Amst). 2016 Nov;47:12-20. doi: 10.1016/j.dnarep.2016.10.004. Epub 2016 Oct 15. Review.

PMID:
27789167
49.

An infernal cross-talk between oncogenic β-catenin and c-Met in hepatocellular carcinoma: Evidence from mouse modeling.

Pascale RM, Feo F, Calvisi DF.

Hepatology. 2016 Nov;64(5):1421-1423. doi: 10.1002/hep.28790. Epub 2016 Sep 30. No abstract available.

PMID:
27596836
50.

The Epidermal Growth Factor Receptor (EGFR) Inhibitor Gefitinib Reduces but Does Not Prevent Tumorigenesis in Chemical and Hormonal Induced Hepatocarcinogenesis Rat Models.

Ribback S, Sailer V, Böhning E, Günther J, Merz J, Steinmüller F, Utpatel K, Cigliano A, Peters K, Pilo MG, Evert M, Calvisi DF, Dombrowski F.

Int J Mol Sci. 2016 Sep 23;17(10). pii: E1618. doi: 10.3390/ijms17101618.

Supplemental Content

Loading ...
Support Center